Semaglutide (Ozempic®; Novo Nordisk A/S, Denmark) is an analog of GLP-1 approved for once-weekly subcutaneous treatment of T2DM in many countries [111]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.